[This corrects the article DOI: 10.1371/journal.pone.0193875.].
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6072129 | PMC |
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0201997 | PLOS |
RSC Adv
January 2025
Department of Chemistry, Division of Science and Technology, University of Education Lahore 54770 Pakistan
[This corrects the article DOI: 10.1039/D3RA08725E.].
View Article and Find Full Text PDFBMJ Open
December 2024
Clinical Sciences, Murdoch Children's Research Institute, Melbourne, Victoria, Australia.
Introduction: Infants born very preterm (VPT, <32 weeks' gestation) are at increased risk for neurodevelopmental impairments including motor, cognitive and behavioural delay. Parents of infants born VPT also have poorer mental health outcomes compared with parents of infants born at term.We have developed an intervention programme called TEDI-Prem (Telehealth for Early Developmental Intervention in babies born very preterm) based on previous research.
View Article and Find Full Text PDFBMJ Open
December 2024
Westmead Institute for Medical Research, Westmead, New South Wales, Australia
Introduction: Diabetic macular oedema (DMO), a serious ocular complication of diabetic retinopathy (DR), is a leading cause of vision impairment worldwide. If left untreated or inadequately treated, DMO can lead to irreversible vision loss and blindness. Intravitreal injections using antivascular endothelial growth factor (anti-VEGF) and laser are the current standard of treatment for DMO.
View Article and Find Full Text PDFCell Death Dis
January 2025
Cancer Institute, University of Mississippi Medical Center, Jackson, MS, USA.
Cureus
December 2024
Ophthalmology, University Hospital of Wales, Cardiff, GBR.
Objective This study aims to evaluate the real-world efficacy of ranibizumab biosimilar (Ongavia), compared to aflibercept (Eylea), in the treatment of treatment-naïve neovascular age-related macular degeneration (nAMD) at a busy tertiary eye care centre. Methods A retrospective analysis of medical records from August 2022 to August 2024 was conducted, comparing treatment outcomes in treatment-naive nAMD patients who received either Ongavia or Eylea intravitreal anti-VEGF (vascular endothelial growth factor) injections under a treat-and-extend protocol. Initial and 12-month outcome measures post-treatment initiation were collected, including best-corrected visual acuity (BCVA), central retinal thickness (CRT), prescribed treatment intervals, actual injection frequency, and the average total number of injections per eye over 12 months.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!